pharmaceutical investing Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
pharmaceutical investing Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635
pharmaceutical investing Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
pharmaceutical investing Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
pharmaceutical investing Aquestive Therapeutics to Present New Clinical Data on Anaphylm Sublingual Film at the 2026 AAAAI Annual Meeting
pharmaceutical investing Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
pharmaceutical investing Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm
pharmaceutical investing Aquestive Therapeutics Announces Regulatory Development for Anaphylm Sublingual Film and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
pharmaceutical investing Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
